|
Abdominal Pain
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormal endocardium morphology
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of aortic valve
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Abnormality of femur morphology
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Acroparesthesia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Classic Fabry disease, an X-linked recessive lysosomal storage disease due to the deficient activity of alpha-galactosidase A, typically presents in early childhood with acroparesthesias, angiokeratomas, hypohidrosis, and corneal dystrophy.
|
16533976 |
2006 |
|
Acute heart failure
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure.
|
28406038 |
2017 |
|
Acute-On-Chronic Liver Failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss the mechanisms related to the alteration of the GLA and their involvement in ACLF pathogenesis and suggest some possible therapeutic options that could modulate the GLA dysfunction.
|
29200007 |
2018 |
|
Airway Obstruction
|
0.010 |
GeneticVariation
|
group |
BEFREE |
PAI-1 gain-of-function genotype, factors increasing PAI-1 levels, and airway obstruction: The GALA II Cohort.
|
28543872 |
2017 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Angina Pectoris
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Angiokeratoma
|
0.410 |
Biomarker
|
disease |
HPO |
|
|
|
|
Angiokeratoma
|
0.410 |
AlteredExpression
|
disease |
BEFREE |
Family A men had markedly decreased α-GalA activity and childhood-onset classic manifestations, except for angiokeratoma and cornea verticillata.
|
28798024 |
2017 |
|
Angiokeratoma
|
0.410 |
Therapeutic
|
disease |
CTD_human |
Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?
|
19925601 |
2010 |
|
Anorexia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Anxiety
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Arthralgia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Arthritis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Perceived Discrimination Associated With Asthma and Related Outcomes in Minority Youth: The GALA II and SAGE II Studies.
|
27916618 |
2017 |
|
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Co-administration of HIV-MVA with rgp140/GLA-AF significantly enhanced antibody responses.
|
30496299 |
2018 |
|
Atrioventricular Block
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Autonomic nervous system disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Fabry's disease is an X-linked lysosomal storage disorder caused by α-galactosidase A gene mutations; neurological manifestations include cerebrovascular accidents, small-fibre neuropathy and autonomic dysfunction.
|
24380807 |
2014 |
|
Back Pain
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The aim of this paper is to present the development, theories, and underlying evidence for 'GLA:D Back' - a group education and exercise program that translates guideline recommendations into a clinician-delivered program for the promotion of self-management in people with persistent/recurrent back pain.
|
30497440 |
2018 |
|
Back Pain
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
GLA:D<sup>®</sup> Back: implementation of group-based patient education integrated with exercises to support self-management of back pain - protocol for a hybrid effectiveness-implementation study.
|
30777049 |
2019 |
|
Bacterial Vaginosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The aim of the current double blind, randomised clinical trial was to assess the efficacy of a probiotic mixture, including Lactobacillus acidophilus GLA-14 and Lactobacillus rhamnosus HN001, in combination with bovine lactoferrin, as adjuvant therapy to metronidazole in women with recurrent BV.
|
30525953 |
2019 |
|
Bacterial Vaginosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
We report here the antimicrobial activities of two commercially existing Lactobacillus strains, Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus GLA-14 strains and their combination (Respecta® probiotic blend) against four different pathogens responsible for both bacterial vaginosis ( Gardenerella vaginalis and Atopobium vaginae) and aerobic vaginitis ( Staphylococcus aureus and Escherichia coli) by co-culturing assay.
|
28580872 |
2017 |